Literature DB >> 11159824

Albumin regulates induction of peroxisome proliferator-activated receptor-gamma (PPARgamma) by 15-deoxy-delta(12-14)-prostaglandin J(2) in vitro and may be an important regulator of PPARgamma function in vivo.

E C Person1, L L Waite, R N Taylor, T S Scanlan.   

Abstract

We observed that serum contains a factor(s) that inhibits the induction of peroxisome proliferator-activated receptor-gamma (PPARgamma) by 15-deoxy-Delta(12,14)-PGJ(2) (15dJ(2)). Ten percent FBS reduces 15dJ(2) induction of PPARgamma from over 150-fold to less than 15-fold in EP-JEG cells, a stably transfected choriocarcinoma cell line that expresses endogenous PPARgamma. By contrast, rosiglitazone, an unrelated pharmacological agonist of PPARgamma, is not inhibited by serum in this cell line. We have identified the inhibitory principal in serum as albumin. Serum albumin binds 15dJ(2) with a dissociation constant of 870 +/- 70 nM, effectively reducing the concentration of 15dJ(2) available to PPARgamma. Heat treatment of serum abolishes the inhibition, providing a way to test eicosanoid compounds independently of albumin's inhibitory effect. It is reasonable to assume that 15dJ(2) or structurally similar compounds or metabolites are the endogenous activators of PPARgamma. Therefore, albumin may be an important regulator of PPARgamma function in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159824     DOI: 10.1210/endo.142.2.7965

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Identification and Molecular Characterization of Peroxisome Proliferator-Activated Receptor δ as a Novel Target for Covalent Modification by 15-Deoxy-Δ12,14-prostaglandin J2.

Authors:  Aravind T Reddy; Sowmya P Lakshmi; Asoka Banno; Raju C Reddy
Journal:  ACS Chem Biol       Date:  2018-11-29       Impact factor: 5.100

2.  Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma.

Authors:  L Chastine Bell-Parikh; Tomomi Ide; John A Lawson; Peter McNamara; Muredach Reilly; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

3.  Albumin-binding and tumor vasculature determine the antitumor effect of 15-deoxy-Delta-(12,14)-prostaglandin-J(2) in vivo.

Authors:  Jai Prakash; Ruchi Bansal; Eduard Post; Alie de Jager-Krikken; Marjolijn N Lub-de Hooge; Klaas Poelstra
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

4.  Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice.

Authors:  Sha-Ron Pierre; Marijke A M Lemmens; Maria E Figueiredo-Pereira
Journal:  J Neuroinflammation       Date:  2009-07-25       Impact factor: 8.322

5.  15-deoxy-Delta12,14-prostaglandin J2 impairs phosphatidylcholine synthesis and induces nuclear accumulation of thiol-modified cytidylyltransferase.

Authors:  Alan J Ryan; Bill B Chen; Prashanth R Vennalaganti; Florita C Henderson; Linda A Tephly; A Brent Carter; Rama K Mallampalli
Journal:  J Biol Chem       Date:  2008-07-08       Impact factor: 5.157

6.  Inhibition of oxidative stress-elicited AKT activation facilitates PPARγ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells.

Authors:  Lanlan Liu; Zhaojuan Yang; Yingqian Xu; Jingyi Li; Dongxu Xu; Li Zhang; Jiabin Sun; Suhua Xia; Feiyan Zou; Yongzhong Liu
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.